[en] Allogeneic hematopoietic stem cell transplantation remains the best curative option for higher-risk myelodysplastic syndrome. The presence of monosomal karyotype and/or complex karyotype abnormalities predicts inferior survival after allo-SCT in MDS patients. Haploidentical allo-SCT has been increasingly used in acute leukemia (AL) and has similar results as using HLA-matched donors, but data on higher-risk MDS is sparse. We compared outcomes in 266 patients with higher-risk MDS after HLA-matched sibling donor (MSD, n = 79), HLA-matched unrelated donor (MUD, n = 139) and HLA haploidentical donor (HID, n = 48) from 2010 to 2019. Median donor age differed between the three groups (p < 0.001). The overall survival was significantly different between the three groups with a better OS observed in the MUD group (p = 0.014). This observation could be explained by a higher progression-free survival with MUD (p = 0.014). The cumulative incidence of grade 2-4 acute GvHD was significantly higher in the HID group (p = 0.051). However, in multivariable analysis, patients transplanted using an HID had comparable mortality to patients transplanted using a MUD (subdistribution hazard ratio [sHR]: 0.58 [0.32-1.07]; p = 0.080) and a MSD ([sHR]: 0.56 [0.28-1.11]; p = 0.094). MUD do not remain a significant positive predictor of survival, suggesting that beyond the donor-recipient HLA matching, the donor age might impact recipient outcome.
Disciplines :
Hematology
Author, co-author :
Michel, Claire; Hematology department, University hospital of Nancy, Nancy, France
Robin, Marie ; Hematology department, Hôpital Saint-Louis, Paris, France
Morisset, Stephane; Biostatistics Consultant, Pérouges, France
Blaise, Didier ; Hematology department, Institut Paoli Calmette, Marseille, France
Maertens, Johan; Hematology department, Hôpital UZ Leuven, Louvain, Belgium
Chevalier, Patrice; Hematology department, University hospital of Nantes, Nantes, France
Castilla-Llorente, Cristina; Hematology department, Institut Gustave Roussy, Paris, France
Forcade, Edouard ; Hematology department, Hôpital Haut-Levêque, Bordeaux, France
Ceballos, Patrice; Hematology department, Hôpital Saint Eloi, Montpellier, France
Yakoug-Agha, Ibrahim ; Hematology department, CHU de Lille, Univ Lille, INSERM U1286, Infinite, Lille, France
Fenaux P, Haase D, Santini V, Sanz GF, Platzbecker U, Mey U, et al. Myelodysplastic syndromes: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up(dagger). Ann Oncol. 2021;32:142–56. DOI: 10.1016/j.annonc.2020.11.002
Platzbecker U, Schetelig J, Finke J, Trenschel R, Scott BL, Kobbe G, et al. Allogeneic hematopoietic cell transplantation in patients age 60-70 years with de novo high-risk myelodysplastic syndrome or secondary acute myelogenous leukemia: comparison with patients lacking donors who received azacitidine. Biol Blood Marrow Transpl. 2012;18:1415–21. DOI: 10.1016/j.bbmt.2012.05.003
Robin M, Porcher R, Ades L, Raffoux E, Michallet M, Francois S, et al. HLA-matched allogeneic stem cell transplantation improves outcome of higher risk myelodysplastic syndrome A prospective study on behalf of SFGM-TC and GFM. Leukemia. 2015;29:1496–501. DOI: 10.1038/leu.2015.37
Kroger N, Sockel K, Wolschke C, Bethge W, Schlenk RF, Wolf D. et al.Comparison Between 5-Azacytidine Treatment and Allogeneic Stem-Cell Transplantation in Elderly Patients With Advanced MDS According to Donor Availability (VidazaAllo Study).J Clin Oncol. 2021;39:3318–27. 10.1200/JCO.20.02724. DOI: 10.1200/JCO.20.02724
Greenberg PL, Tuechler H, Schanz J, Sanz G, Garcia-Manero G, Sole F, et al. Revised international prognostic scoring system for myelodysplastic syndromes. Blood. 2012;120:2454–65. DOI: 10.1182/blood-2012-03-420489
Greenberg P, Cox C, LeBeau MM, Fenaux P, Morel P, Sanz G, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood. 1997;89:2079–88. DOI: 10.1182/blood.V89.6.2079
Gauthier J, Damaj G, Langlois C, Robin M, Michallet M, Chevallier P, et al. Contribution of revised international prognostic scoring system cytogenetics to predict outcome after allogeneic stem cell transplantation for myelodysplastic syndromes: A study from the French Society of bone marrow transplantation and cellular therapy. Transplantation. 2015;99:1672–80. DOI: 10.1097/TP.0000000000000649
Gragert L, Eapen M, Williams E, Freeman J, Spellman S, Baitty R, et al. HLA match likelihoods for hematopoietic stem-cell grafts in the U.S. registry. N Engl J Med. 2014;371:339–48. DOI: 10.1056/NEJMsa1311707
Santoro N, Labopin M, Giannotti F, Ehninger G, Niederwieser D, Brecht A. et al. Unmanipulated haploidentical in comparison with matched unrelated donor stem cell transplantation in patients 60 years and older with acute myeloid leukemia: A comparative study on behalf of the ALWP of the EBMT. J Hematol Oncol. 2018;11:55. DOI: 10.1186/s13045-018-0598-0
Salvatore D, Labopin M, Ruggeri A, Battipaglia G, Ghavamzadeh A, Ciceri F, et al. Outcomes of hematopoietic stem cell transplantation from unmanipulated haploidentical versus matched sibling donor in patients with acute myeloid leukemia in first complete remission with intermediate or high-risk cytogenetics: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. Haematologica. 2018;103:1317–28. DOI: 10.3324/haematol.2018.189258
Battipaglia G, Boumendil A, Labopin M, Ciceri F, Tischer J, Stelljes M, et al. Unmanipulated haploidentical versus HLA-matched sibling allogeneic hematopoietic stem cell transplantation in relapsed/refractory acute myeloid leukemia: a retrospective study on behalf of the ALWP of the EBMT. Bone Marrow Transpl. 2019;54:1499–510. DOI: 10.1038/s41409-019-0459-7
Nagler A, Labopin M, Houhou M, Aljurf M, Mousavi A, Hamladji RM, et al. Outcome of haploidentical versus matched sibling donors in hematopoietic stem cell transplantation for adult patients with acute lymphoblastic leukemia: A study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. J Hematol Oncol. 2021;14:53. DOI: 10.1186/s13045-021-01065-7
Ciurea SO, Zhang MJ, Bacigalupo AA, Bashey A, Appelbaum FR, Aljitawi OS, et al. Haploidentical transplant with posttransplant cyclophosphamide vs matched unrelated donor transplant for acute myeloid leukemia. Blood. 2015;126:1033–40. DOI: 10.1182/blood-2015-04-639831
Wang Y, Liu QF, Xu LP, Liu KY, Zhang XH, Ma X, et al. Haploidentical vs identical-sibling transplant for AML in remission: A multicenter, prospective study. Blood. 2015;125:3956–62. DOI: 10.1182/blood-2015-02-627786
Lorentino F, Labopin M, Bernardi M, Ciceri F, Socie G, Cornelissen JJ, et al. Comparable outcomes of haploidentical, 10/10 and 9/10 unrelated donor transplantation in adverse karyotype AML in first complete remission. Am J Hematol. 2018;93:1236–44. DOI: 10.1002/ajh.25231
Chang YJ, Wang Y, Liu YR, Xu LP, Zhang XH, Chen H, et al. Haploidentical allograft is superior to matched sibling donor allograft in eradicating pre-transplantation minimal residual disease of AML patients as determined by multiparameter flow cytometry: a retrospective and prospective analysis. J Hematol Oncol. 2017;10:134. DOI: 10.1186/s13045-017-0502-3
Wang Y, Wang HX, Lai YR, Sun ZM, Wu DP, Jiang M, et al. Haploidentical transplant for myelodysplastic syndrome: registry-based comparison with identical sibling transplant. Leukemia. 2016;30:2055–63. DOI: 10.1038/leu.2016.110
Grunwald MR, Zhang MJ, Elmariah H, Johnson MH, St Martin A, Bashey A, et al. Alternative donor transplantation for myelodysplastic syndromes: haploidentical relative and matched unrelated donors. Blood Adv. 2021;5:975–83. DOI: 10.1182/bloodadvances.2020003654
Schanz J, Tuchler H, Sole F, Mallo M, Luno E, Cervera J, et al. New comprehensive cytogenetic scoring system for primary myelodysplastic syndromes (MDS) and oligoblastic acute myeloid leukemia after MDS derived from an international database merge. J Clin Oncol. 2012;30:820–9. DOI: 10.1200/JCO.2011.35.6394
Cheson BD, Greenberg PL, Bennett JM, Lowenberg B, Wijermans PW, Nimer SD, et al. Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood. 2006;108:419–25. DOI: 10.1182/blood-2005-10-4149
Przepiorka D, Weisdorf D, Martin P, Klingemann HG, Beatty P, Hows J, et al. 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transpl. 1995;15:825–8.
Filipovich AH, Weisdorf D, Pavletic S, Socie G, Wingard JR, Lee SJ, et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transpl. 2005;11:945–56. DOI: 10.1016/j.bbmt.2005.09.004
Holtan SG, DeFor TE, Lazaryan A, Bejanyan N, Arora M, Brunstein CG, et al. Composite end point of graft-versus-host disease-free, relapse-free survival after allogeneic hematopoietic cell transplantation. Blood. 2015;125:1333–8. DOI: 10.1182/blood-2014-10-609032
Kunacheewa C, Ungprasert P, Phikulsod P, Issaragrisil S, Owattanapanich W. Comparative efficacy and clinical outcomes of haploidentical stem cell transplantation to other stem sources for treatment in acute myeloid leukemia and myelodysplastic syndrome patients: A systematic review and meta-analysis. Cell Transpl. 2020;29:963689720904965. DOI: 10.1177/0963689720904965
van Gelder M, de Wreede LC, Schetelig J, van Biezen A, Volin L, Maertens J, et al. Monosomal karyotype predicts poor survival after allogeneic stem cell transplantation in chromosome 7 abnormal myelodysplastic syndrome and secondary acute myeloid leukemia. Leukemia. 2013;27:879–88. DOI: 10.1038/leu.2012.297
Della Porta MG, Alessandrino EP, Bacigalupo A, van Lint MT, Malcovati L, Pascutto C, et al. Predictive factors for the outcome of allogeneic transplantation in patients with MDS stratified according to the revised IPSS-R. Blood. 2014;123:2333–42. DOI: 10.1182/blood-2013-12-542720
Kulasekararaj AG, Smith AE, Mian SA, Mohamedali AM, Krishnamurthy P, Lea NC, et al. TP53 mutations in myelodysplastic syndrome are strongly correlated with aberrations of chromosome 5, and correlate with adverse prognosis. Br J Haematol. 2013;160:660–72. DOI: 10.1111/bjh.12203
van Roessel I, Prockop S, Klein E, Boulad F, Scaradavou A, Spitzer B, et al. Early CD4+ T cell reconstitution as predictor of outcomes after allogeneic hematopoietic cell transplantation. Cytotherapy. 2020;22:503–10. DOI: 10.1016/j.jcyt.2020.05.005
Retiere C, Willem C, Guillaume T, Vie H, Gautreau-Rolland L, Scotet E, et al. Impact on early outcomes and immune reconstitution of high-dose post-transplant cyclophosphamide vs anti-thymocyte globulin after reduced intensity conditioning peripheral blood stem cell allogeneic transplantation. Oncotarget. 2018;9:11451–64. DOI: 10.18632/oncotarget.24328
Kroger N, Iacobelli S, Franke GN, Platzbecker U, Uddin R, Hubel K, et al. Dose-reduced versus standard conditioning followed by allogeneic stem-cell transplantation for patients with myelodysplastic syndrome: A prospective randomized phase III study of the EBMT (RICMAC Trial). J Clin Oncol. 2017;35:2157–64. DOI: 10.1200/JCO.2016.70.7349
Campidelli A, Robin M, Remen T, Luc A, Labussiere-Wallet H, Dulery R, et al. On Behalf of the SFGM-TC: Retrospective comparison of reduced and higher intensity conditioning for high-risk myelodysplastic syndrome treated with allogeneic stem-cell transplantation. Clin Lymphoma Myeloma Leuk. 2022;22:34–43. DOI: 10.1016/j.clml.2021.07.027
Gooptu M, Romee R, St Martin A, Arora M, Al Malki M, Antin JH, et al. HLA-haploidentical vs matched unrelated donor transplants with posttransplant cyclophosphamide-based prophylaxis. Blood. 2021;138:273–82. DOI: 10.1182/blood.2021011281
Raj K, Eikema DJ, Sheth V, Koster L, de Wreede LC, Blaise D, et al. Comparison of outcomes for HLA-matched sibling and haplo-identical donors in Myelodysplastic syndromes: Report from the chronic malignancies working party of EBMT. Blood Cancer J. 2022;12:140. DOI: 10.1038/s41408-022-00729-y